섬유소용해 토끼에서 혈전 탄성 묘사 검사를 이용한 Aprotinin과 Tranexamic Acid의 항섬유소용해 효과의 비교

다국어 초록 (Multilingual Abstract)

Background: Aprotinin and tranexamic acid are commonly used antifibrinolytics during liver transplantation, or cardiac surgery. However, it is not clear which drug is more effective to ameliorate the fibrinolysis. The aim of the study was to investigate the antifibrinolytic effect of both drugs at previously reported blood concentration and dose.
Methods: After inducing fibrinolysis by administering recombinant tissue plasminogen activator to rabbits, we checked the in vitro and in vivo antifibrinolytic effects at previously reported blood concentration and dose, and determined the minimum antifibrinolytic blood concentration. The previously reported blood concentration was 200 KIU/ml for aprotinin and 10 mcg/ml for tranexamic acid, and the previously reported dose was 4 mg/kg bolus plus 1 mg/kg/hr infusion for aprotinin and 10 mg/kg bolus plus 1 mg/kg/hr for tranexamic acid.
Results: In vitro experiment, there was effective antifibrinolytic action at previously reported blood concentration of aprotinin and the minimum antifibrinolytic blood concentration was 40 KIU/ml. For tranexamic acid, there was no antifibrinolytic action at previously reported blood concentration and the minimum antifibrinolytic blood concentration was 100 mcg/ml. In vivo experiment, there was antifibrinolytic action at previously reported dose of aprotinin and the minimum antifibrinolytic dose was 60% of previously reported dose. For tranexamic acid, there was no antifibrinolytic action at previously reported dose and the minimum antifibrinolytic dose was 10 times previously reported dose.
Conclusions: The previously reported blood concentration and dose of aprotinin were greater and those of tranexamic acid were less than the minimum antifibrinolytic blood concentration and dose. (Korean J Anesthesiol 2005; 49: 227～34)

참고문헌 (Reference)

1 "as well as plasminogen activators contribute to the state during orthotopic liver transplantation" 568-72, transplantation1993

2 "Tranexamic acid compared with aprotinin in primary elective heart operations:effects on perioperative bleeding and allogenic transfusions" 120 : 520-7, 2000

3 "Tissue plasminogen activator can effectively declot peritoneal dialysis cathters" 36 : 675-, 2000

4 "Time course of thrombolysis induced by intravenous bolus or infusions of tissue plasminogen activator in a rabbit jugular vein thrombosis model" 79 : 125-33, 1989

5 "Thromboelastography in liver transplantation" 21 : 34-44, 1995

6 "Thrombelastography" 69 : 307-13, 1992

7 "The use of high dose aprotinin in liver transplantation:the influence on fibrinolysis and blood loss" 63 : 287-97, 1991

8 "The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation:a comparative study" 10 : 279-84, 2004

9 "The dose-response relationship of tranexamic acid" 82 : 383-92, 1995

10 "The absorption,distribution,and excretion of e-aminocaproic acid following oral or intravenous administration to man" 59 : 15-24, 1962

11 "Systemic hemostatic medications for reducing surgical blood loss" 35 : 925-34, 2001

12 "Systemic fibrinogenolysis in liver transplantation" 22 : 2303-4, 1990

13 "Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplanatation 1989" 978-84,

14 "Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA" 642-58,

15 "Reduction in post operative blood loss in patients having open heart reoperation using high dose aprotinin(Trasylol)" 67 : 1987

16 "Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin(Trasylol)" 97 : 364-72, 1989

17 "Plasma aprotinin concentration during cardiac surgery:full-versus half-dose regimens" 91 : 257-64, 2000

18 "Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator.correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction" 80 : 1222-30, 1989

19 "Natural and synthetic antifibrinolytics in adult cardiac surgery" 1104-12,

20 "Mediators of fibrinolysis in orthotopic liver transplantation" 10 : 24-7, 1996

21 "Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits" 67 : 1493-7, 1986

22 "In vitro comparison of fibrinolytic activity of plasmonogen activators using a thromboelastographic method:in vivo evaluation of the β- chain-streptokinase complex in the dog model using pretitered doses" 56 : 71-9, 1986

23 "Impact of tranexamic acid vs aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass" 121-6, 2004

24 "Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes.Biochemical and multicenter validation of a two site immunosorbent assay" 61 : 409-14, 1989

25 "High-dose aprotinin therapy:A review of the first five years' experience" 6 : 76-100, 1992

26 "Heparin-coated bypass circuits(Carmeda)suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery" 12 : 299-304, 1998

27 "Hemostsis changes during cardiopulmonary bypass surgery" 281-92, seminthrombhemost1985

28 "Fibrinolytic changes and the influence of the early perfusate in orthotopic liver transplantation with intraoperative aprotinin treatment" 23 : 1936-7, 1991

29 "Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin" 58 : 1356-60, 1994

30 "Fibrinolysis during liver transplantation in humans:Role of tissue-type plasminogen activator" 71 : 1090-5, 1988

31 "Evaluation of the contribution of platelets to clot strength by thromboelstography in rabbits:the role of tissue factor and cytochalasin D" 91 : 35-9, 2000

32 "Enhancement of neointima formation with tissue type plasminogen activator" 33 : 821-8, 2001

33 "Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass" 44 : 640-5, 1987

34 "Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting" 108 : 99-108, 1994

35 "Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding" 92 : 674-82, 2000

36 "Comparative effects of small and large aprotinin doses on bleeding during orthotopic liver transplantation" 80 : 349-52, 1995

37 "Clinical application of inhibitors of fibrinolysis" 29 : 236-61, 1985

38 "Citrate storage affects thromboelastograph analysis" 92 : 1242-9, 2000

39 "Changes of plasminogen-plasmin system in malignant ascites" 1 : 57-65, 1994

40 "Baseline computed tomography changes and clinical outcome after thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke" 11 : 101-4, 2001

41 "Aprotinin and transfusion requirements in orthotopic liver transplantation:a multicentre randomised double-blind study" 355 : 1303-9, 2000

42 "Aprotinin and tranexamic acid for high transfusion risk cardiac surgery" 69 : 808-16, 2000

43 "Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery" 35 : 1075-84, 2001

44 "Animal experiment methods for the testing of fibrinolytic and antifibrinolytic agents" 92 : 84-9, 1969

45 "Analysis of coagulation and fibrinolysis during intravenous infusion of rh tissue-type plasminogen activator in patients with acute myocardial infarction" 73 : 511-7, 1986